Moviprep (Ascorbic Acid, Sodium Ascorbate, Potassium Chloride, Sodium Chloride, Sodium Sulfate Anhydrous, Macr)

Polyethylene glycol 3350 is a high‑molecular‑weight polymer that is minimally absorbed. When ingested with electrolytes, it creates an osmotic gradient that draws water into the intestinal lumen, increasing fluid volume and stimulating peristalsis, which results in swift bowel evacuation.

The exact dosing regimen for Moviprep is determined by the prescribing clinician based on the procedure, patient characteristics and local guidelines. The product is supplied in sachets that are reconstituted with water, and the prescriber specifies the number of sachets and timing of intake.

Safety data for Moviprep in pregnant or lactating women are limited, and the product is generally not recommended unless the potential benefit outweighs the risk. Clinicians should evaluate each case individually and consider alternative bowel‑preparation methods when possible.

To place an order, submit an enquiry on the Moviprep product page at gnhindia.com, indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with sodium‑picosulfate‑based regimens, Moviprep provides a polyethylene glycol‑based osmotic cleanse that is generally well‑tolerated and maintains electrolyte balance due to its added salts. It may require a larger fluid volume but offers consistent bowel clearance across a broad patient population.

Store Moviprep at ambient temperature, preferably below 25 °C, in its original packaging. Protect the sachets from moisture and direct sunlight to preserve product stability. Do not refrigerate or freeze the powder.

Each sachet of Moviprep is mixed with a specified amount of water (usually 125 mL) to create a clear solution. The patient drinks the solution according to the prescriber’s schedule, often split into two doses separated by a few hours, while maintaining additional fluid intake as instructed.

The most serious risks include severe dehydration, marked electrolyte disturbances (such as hyponatremia or hypokalemia), acute renal impairment and, rarely, colonic perforation. Patients should be monitored for signs of these complications, especially if they have pre‑existing kidney disease or fluid‑balance disorders.

Moviprep is contraindicated in patients with known or suspected mechanical bowel obstruction, intestinal perforation, severe inflammatory bowel disease flare, or hypersensitivity to any component of the formulation. Caution is also advised for individuals with significant renal insufficiency or uncontrolled electrolyte abnormalities.